Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?
作者信息
Lee Michael S, Kopetz Scott
机构信息
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Natl Cancer Inst. 2022 Feb 7;114(2):176-178. doi: 10.1093/jnci/djab170.
Abstract
摘要
相似文献
1
Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?
J Natl Cancer Inst. 2022 Feb 7;114(2):176-178. doi: 10.1093/jnci/djab170.
2
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
World J Gastroenterol. 2016 Dec 28;22(48):10680-10686. doi: 10.3748/wjg.v22.i48.10680.
3
Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Mol Oncol. 2017 May;11(5):470-490. doi: 10.1002/1878-0261.12040. Epub 2017 Mar 27.
4
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9.
5
Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
J Biol Chem. 2014 Mar 28;289(13):9247-53. doi: 10.1074/jbc.M114.551143. Epub 2014 Feb 19.
6
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Bull Cancer. 2022 Jan;109(1):76-82. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
7
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Eur Urol Oncol. 2020 Oct;3(5):594-611. doi: 10.1016/j.euo.2020.07.005. Epub 2020 Aug 17.
8
PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Jpn J Clin Oncol. 2019 Aug 1;49(8):703-707. doi: 10.1093/jjco/hyz090.
9
Biomarkers for Homologous Recombination Deficiency in Cancer.
J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085.
10
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
Cancer Res. 2011 Apr 1;71(7):2632-42. doi: 10.1158/0008-5472.CAN-10-1120. Epub 2011 Feb 7.
引用本文的文献
1
Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience.
Mutagenesis. 2025 Mar 15;40(1):20-29. doi: 10.1093/mutage/geae014.
2
PARP Inhibitors in Colorectal Malignancies: A 2023 Update.
Rev Recent Clin Trials. 2024;19(2):101-108. doi: 10.2174/0115748871260815231116060817.
3
HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data.
Front Genet. 2022 Sep 28;13:990244. doi: 10.3389/fgene.2022.990244. eCollection 2022.
本文引用的文献
1
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
J Natl Cancer Inst. 2022 Feb 7;114(2):271-279. doi: 10.1093/jnci/djab169.
2
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.
Clin Cancer Res. 2021 Jun 1;27(11):3234-3242. doi: 10.1158/1078-0432.CCR-20-3635. Epub 2021 Mar 25.
3
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
4
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Br J Surg. 2020 Jul;107(8):951-959. doi: 10.1002/bjs.11603. Epub 2020 Apr 16.
5
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
6
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
7
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Clin Cancer Res. 2020 Mar 15;26(6):1372-1384. doi: 10.1158/1078-0432.CCR-19-2409. Epub 2019 Dec 12.
8
DNA double-strand break repair-pathway choice in somatic mammalian cells.
Nat Rev Mol Cell Biol. 2019 Nov;20(11):698-714. doi: 10.1038/s41580-019-0152-0. Epub 2019 Jul 1.
9
The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195. doi: 10.1200/EDBK_238473. Epub 2019 May 17.
10
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1.
Zotero 插件